Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1307240 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Given the gut microbiota involve aging processing, we performed comparative analysis of gut bacteriophage between older and young subjects using next-generation sequencing (NGS). In our previous study, we found that the Ruminococcaceae is higher in aged subjects comparing to young one. To identify the bacteriophage targeting to the Ruminococcaceae, we also access the composition of phage in the Ruminococcaceae (ATCC, TSD-27) after incubated with human stool samples. The Lactobacillus (ATCC, LGG) targeting phage was used as the control. The virome sequencing analysis using NGS indicated that Myoviridae are high enrich in young subjects and predominate in TSD-27 targeting phage.
2022-07-20 | GSE196622 | GEO
Project description:Genome sequence of bacteriophage HM2, a lytic phage for solventogenic Clostridium
| PRJEB14799 | ENA
Project description:Mucin hypersecretion, a hallmark of chronic respiratory diseases (CRD), creates a complex microenvironment that reshapes host immunity and microbial behavior. However, its impact on bacteriophage therapy remains poorly understood. Here, we demonstrate that, despite reducing Pseudomonas aeruginosa internalization, mucin increases bacterial-induced cytotoxicity and inflammation in airway epithelial cells, while driving CRD-like transcriptional changes, including hypoxia and stress responses. Mucin selectively downregulates virulence factors without impairing bacterial growth. P. aeruginosa-infecting bacteriophage DMS3vir retained full lytic activity in mucin-rich conditions and, in synergy with mucin, enhanced epithelial cells protection against cytotoxicity. DMS3vir also reduced IL-8 gene expression without triggering antiviral responses. Furthermore, mucin shaped phage-resistant P. aeruginosa phenotypes, altering pigmentation, pigmentation, pyocyanin production, and motility. These changes influenced virulence trade-offs. These findings uncover the dual role of mucins as modulators of infection and sensitizers to phage protection, paving the way for optimized, mucosa-adapted phage therapies in chronic lung diseases.
2025-10-19 | GSE307737 | GEO